The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
Japan Tobacco said on November 29 that it will return exclusive Japanese rights for six HIV agents of Gilead Sciences to the big biotech in 2019 as they wrapped up their talks launched earlier this year to terminate their 15-year-old…
To read the full story
Related Article
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
- Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
December 17, 2018
- Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
BUSINESS
- Chugai’s DMD Gene Therapy Snags Conditional Approval in Japan
May 14, 2025
- Sumitomo Charts Revival Plan, Eyes 250 Billion Yen with 3 Key Meds by FY2027
May 14, 2025
- Suzuken Forms Tie-Up with Dongwon Group in South Korea
May 14, 2025
- Sumitomo Pharma Logs 1st Operating Profit in 3 Years in FY2024
May 14, 2025
- Mitsubishi Tanabe’s Net Profit More than Halves after Buyout Package
May 14, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…